Pharma News

Sanofi, Cipla announce exclusive distribution partnership of CNS product

Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category. 

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.

Medlarge

Recent Posts

Delhi reports first case of Japanese Encephalitis

The national capital has reported an ‘isolated’ case of Japanese Encephalitis (JE) in a 72-year-old…

3 days ago

90 drug samples tested in October found not of standard quality

The Central Drugs Standard Control Organisation found 56 drug samples tested in the central drug…

3 days ago

Black tumor removed from the brain of 72-year-old woman

A team of doctors have removed a rare and complex black brain tumor from the…

1 week ago

Lupin’s ESG score rises to 76 in S&P Global ESG Ratings

Global pharma major Lupin Limited (Lupin) today announced its S&P Global ESG scores have moved…

1 week ago

After Tata Memorial, AIIMS oncology experts raises question over Sidhu’s cancer cure claims

Following a statement from Tata Memorial Centre, Dr. Abhishek Shankar, a senior oncologist from AIIMS…

1 week ago

Tata Memorial institute raises questions over Navjot Singh Sidhu’s claim remedy on cancer

Reacting to Navjot Singh Sidhu’s claim on wife’s cancer treatment and outcome, a group of oncologists…

1 week ago